title: [Hypertension in the course of primary aldosteronism during pregnancy].
abstract: Hypertension is one of the most common cardiovascular diseases during pregnancy. Primary hyperaldosteronism (PHA) is the most frequent endocrinological, secondary cause of hypertension, rarely diagnosed in pregnant women. In the available literature about 50 cases of PHA in pregnant women have been described. PHA is often a cause of resistant hypertension. PHA can cause life-threatening complications both for the pregnant woman and the fetus. Diagnosis of PHA in pregnancy is difficult due to the antagonistic effect of progesterone on aldosterone, physiological increase of aldosterone release during gestation and frequent normokalaemic clinical course. Typical pharmacological treatment of PHA is limited due to the anti‑androgenic effect of spironolactone, lack of data concerning the safety of eplerenone and limited access to amiloride in Poland. Surgical treatment is a therapeutic option only in early pregnancy. This paper presents the current state of knowledge on diagnostic methods and treatment of PHA in pregnant women and a systematic review of cases described in the literature.
authors.affiliation: Zakład Patofizjologii Katedry Patofizjologii Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Wyskida
authors.affiliation: Zakład Promocji Zdrowia i Leczenia Otyłości Katedry Patofizjologii Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Wyskida
authors.affiliation: Zakład Promocji Zdrowia i Leczenia Otyłości Katedry Patofizjologii Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Olszanecka-Glinianowicz
authors.affiliation: Klinika Intensywnej Terapii i Patologii Noworodka Katedry Pediatrii Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Iwona
authors.initials: I
authors.lastname: Maruniak-Chudek
authors.affiliation: Katedra i Klinika Perinatologii i Ginekologii Wydziału Nauk o Zdrowiu Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Jerzy
authors.initials: J
authors.lastname: Sikora
authors.affiliation: Zakład Patofizjologii Katedry Patofizjologii Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach.
authors.forename: Jerzy
authors.initials: J
authors.lastname: Chudek
mesh_terms: D062646:Acid Sensing Ion Channel Blockers / Q000627:therapeutic use; D000450:Aldosterone / Q000378:metabolism; D000584:Amiloride / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077545:Eplerenone; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis* / Q000188:drug therapy*; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy*; D011044:Poland; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000188:drug therapy*; D011374:Progesterone / Q000627:therapeutic use; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D062646:Acid Sensing Ion Channel Blockers; D000959:Antihypertensive Agents; D013148:Spironolactone; D000450:Aldosterone; D011374:Progesterone; D000077545:Eplerenone; D000584:Amiloride